[Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma]

Isao Matsuda; Yuki Mori; Yasunori Nakagawa; Masakazu Sawanobori; Naoki Uemura; Kenshi Suzuki

[Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma]

Rinsho Ketsueki. 2005 Dec;46(12):1293-7.

[Article in Japanese]

Authors

Isao Matsuda¹, Yuki Mori, Yasunori Nakagawa, Masakazu Sawanobori, Naoki Uemura, Kenshi Suzuki

Affiliation

¹ Department of Hematology, Japanese Red Cross Medical Center.

PMID: 16447802

Abstract

Stratification of patients with multiple myeloma (MM) may be important. We investigated 138 MM patients, focusing on correlations between CD20 expression, 11 ; 14 translocation, morphology of MM cells, cyclin D1 immunostaining, and the prognosis. About 15% of patients (7/47cases) were CD20-positive, small mature MM cells, with positive cyclin D1 in the nucleus and 11; 14 translocation. Two color analysis of CD38 x CD20 antigens may be necessary to investigate CD20 expression on MM cells. Rituximab may be effective for the treatment of CD20-positive MM.

Publication types

English Abstract

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 / analysis*
Antineoplastic Agents / therapeutic use
Chromosomes, Human, Pair 11 / genetics
Chromosomes, Human, Pair 14 / genetics
Cyclin D1 / analysis
Female
Gene Expression
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy
Multiple Myeloma / genetics*
Multiple Myeloma / immunology
Multiple Myeloma / pathology*
Plasma Cells / pathology*
Prognosis
Rituximab
Translocation, Genetic / genetics*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Antineoplastic Agents
Cyclin D1
Rituximab